Publication for CD2 and BTLA
| Species | Symbol | Function* | Entrez Gene ID* | Other ID | Gene coexpression |
CoexViewer |
|---|---|---|---|---|---|---|
| hsa | CD2 | CD2 molecule | 914 | [link] | ||
| hsa | BTLA | B and T lymphocyte associated | 151888 |
| Pubmed ID | Priority | Text |
|---|---|---|
| 29588478 | 0.97 | BTLA+ cDC1s (turquoise nodes) and the remaining 4 corresponding to CD11c+CD1c+CD2+ cDC2s (red nodes). |
| 22548114 | 0.96 | B- and T-lymphocyte attenuator (BTLA; CD272); (2) CD2/signaling lymphocyte activation molecule (SLAM) family including SLAM (CD150), 2B4 (CD244), and CD48; (3) Ig family including T-cell immunoglobulin mucin-3 (TIM-3), CD160, and Lymphocyte-activation gene 3 (Lag-3); and (4) TNF-receptor superfamily including CD27. |
| 25866635 | 0.96 | BTLA); and (v) cell interactions and TL functional avidity (CD3, CD8, CD2, CD58, CD18, CD54). |
| 31360302 | 0.96 | CD2, and BTLA remain highly complementary in our joint analysis of complementarity to therapies directed at PDCD1 and to CTLA4 (Figure 2B-2D, Supplementary Figure 4). |
| 29313948 | 0.93 | BTLA and CD26 for CD141+ myeloid cDC1, and CD2, FcepsilonR1 and SIRPA for CD1c+ myeloid cDC22, 3, 4 (Table 1). |
The preparation time of this page was 0.0 [sec].
